Apolipoprotein E4 (APOE4) is the most significant genetic risk factor for late-onset Alzheimer's disease (AD), approximately tripling the risk for carriers compared to non-carriersChen J 2024, Cryo-EM structure of APOE4 reveals structural determinants of aggregation. The APOE gene exists in three common alleles: APOE2, APOE3, and APOE4, with APOE4 being the risk allele and APOE2 being protective. Understanding the mechanisms by which APOE4 increases AD risk is critical for developing effective therapeutic strategies.
The APOE gene is located on chromosome 19q13.32 and encodes apolipoprotein E, a 299-amino acid glycoprotein involved in lipid transport and metabolism. APOE is produced primarily in the liver and brain, with astrocytes and microglia being the main sources in the central nervous systemBell RD 2025, Cyclophilin A-MMP9 mediates APOE4-induced blood-brain barrier dysfunction. APOE4 carriers show distinct patterns of astrocyte dysfunction that contribute to disease pathogenesisHaney MS 2025, APOE4 drives astrocyte metabolic dysfunction through mitochondrial fragmentation.
APOE contains two structural domains:
The APOE4 isoform differs from APOE3 at position 112 (cysteine → arginine), which alters protein structure and functionSperling RA 2024, Precision medicine trial design incorporating APOE4 status.
APOE4 carriers show increased amyloid-beta (Aβ) accumulation in the brain through multiple mechanisms:
Beyond amyloid, APOE4 influences tau pathology through several pathwaysShi Y 2017, ApoE4 markedly exacerbates tau-mediated neurodegenerationZhao N 2023, APOE4 exacerbates tau-mediated neurodegeneration through microglial activation:
APOE4 significantly impacts neuroinflammation in ADJiang T 2024, APOE4 and neuroinflammation in AlzheimerSong X 2025, APOE4 exacerbates microglial senescence and inflammaging in AD brain:
APOE4 contributes to synaptic dysfunction through multiple mechanismsLane RF 2023, APOE4 and synaptic function in AlzheimerBuonanno A 2024, APOE4 and synaptic dysfunction: molecular mechanismsKim J 2024, The role of APOE in synaptic plasticity and memory:
APOE4 carriers have increased risk of cerebral amyloid angiopathy (CAA)Liu Q 2024, APOE4 and cerebral amyloid angiopathy: mechanisms and clinical implicationsChen Y 2025, APOE4 impairs glymphatic clearance through perivascular pathway dysfunctionNarayan P 2024, APOE4 and blood-brain barrier transport of amyloid-beta:
APOE4 contributes to vascular contributions to cognitive impairment through multiple pathwaysMartinez R 2024, APOE4 and vascular contributions to cognitive impairmentLiu CC 2025, APOE4-driven lipidomic alterations in brain parenchymal and vascular compartm...:
APOE4 status influences CSF proteomic signatures that can predict cognitive declinePatel D 2025, APOE4-associated CSF proteomic signatures predict cognitive declineYang L 2025, APOE4 homozygosity defines a distinct endophenotype in Alzheimer:
| Genotype | Relative AD Risk | Age of Onset |
|---|---|---|
| APOE3/APOE3 | 1.0 (reference) | ~75 years |
| APOE3/APOE4 | ~3-fold | ~70 years |
| APOE4/APOE4 | ~12-fold | ~65 years |
| APOE2/APOE3 | ~0.6 (protective) | Later |
APOE genotyping can provide risk information but has limitations:
APOE4-related therapeutic strategies include:
Risk reduction strategies for APOE4 carriers:
APOE4 frequency and impact varies across populations:
Several therapeutic strategies targeting APOE4 are in development: